Peptide ·Insufficient evidence ·Reviewed May 2026
Pentadeca Arginate is marketed as an arginate-salt form of the BPC-157 pentadecapeptide for tissue repair and inflammation. It is not FDA-approved, and direct published human trials of PDA itself are essentially absent. Claims are mostly extrapolated from BPC-157 animal literature and should be considered research-use only.
The bottom line
Evidence rating insufficient. Most-documented uses: bpc-157-related tissue repair claims, animal wound-healing literature for related peptide, no direct high-quality human pda evidence. 3 sources indexed (1997–2025), with 3 interaction records on file.
Core mechanism
PDA is described commercially as the BPC-157 peptide sequence paired with an arginine counterion, proposed to improve stability or formulation characteristics. BPC-157 literature suggests effects on nitric oxide pathways, angiogenesis, tendon and gut injury models, and cytoprotection, but most data come from animal models. The arginate salt should not be assumed to have proven human bioavailability, safety, or efficacy.1,3
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Laboratory Research Reagent.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Dose: No FDA-approved dose
Timing: Not applicable
Seek diagnosis, rehabilitation, and imaging when indicated.
Dose: No approved dose
Timing: Not applicable
GI bleeding, ulcers, and IBD require standard medical care.
Where this appears in the symptom-to-supplement map, ranked by relevance.
BPC-157 wound data are preclinical and not PDA-specific.2,1
Nonhealing wounds need medical workup.
Repair claims are extrapolated from BPC-157 animal models.
Use rehabilitation and diagnosis for tendon injury.
Gastric cytoprotection claims are not validated for human PDA use.2,3
Evaluate ulcers, bleeding, and medication causes.
PDA is marketed as an arginate salt and related BPC-157 animal data involve nitric oxide pathways; L-citrulline can raise nitric oxide availability.
Recommendation: Avoid combining in people with hypotension, nitrate use, or uncontrolled cardiovascular disease.
Garlic may increase bleeding tendency, which matters around injury, procedures, or injections.
Recommendation: Avoid around surgery, serious injury, or invasive peptide use unless approved.
Fish oil can add bruising risk around injections or procedures.
Recommendation: Disclose use before procedures and avoid self-injection.
Search all 3 interaction records for Pentadeca Arginate (PDA) →
Numbered references. Citations throughout the page link here.
Many proposed applications are preclinical
Broad wound model literature reviewed
BPC-157 modified L-NAME and L-arginine effects
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
